Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Do simulations enhance student learning? An empirical evaluation of an IR simulation

Science education

Shellman SM, Turan K.
GSID: VZDezMLOxUUJ
SM Shellman, K Turan - Journal of Political Science Education, 2006 - Taylor & Francis

There is a nascent literature on the question of whether active learning methods, and in particular simulation methods, enhance student learning. In this article, the authors evaluate …

Cite
Shellman, S. M., & Turan, K. (2006). Do simulations enhance student learning? An empirical evaluation of an IR simulation. Journal of Political Science Education, 2(1), 19-32.
Shellman, Stephen M., and Kürşad Turan. "Do simulations enhance student learning? An empirical evaluation of an IR simulation." Journal of Political Science Education 2.1 (2006): 19-32.
Copy Download .nbib Format: MLA
Metabolic network motifs can provide novel insights into evolution: The evolutionary origin of Eukaryotic organelles as a case study.

Computational biology and chemistry

Shellman ER, Chen Y, Lin X, Burant CF, Schnell S.
PMID: 25462333
Comput Biol Chem. 2014 Dec;53:242-250. doi: 10.1016/j.compbiolchem.2014.09.006. Epub 2014 Sep 21.

Phylogenetic trees are typically constructed using genetic and genomic data, and provide robust evolutionary relationships of species from the genomic point of view. We present an application of network motif mining and analysis of metabolic pathways that when used...

Cite
Shellman ER, Chen Y, Lin X, et al. Metabolic network motifs can provide novel insights into evolution: The evolutionary origin of Eukaryotic organelles as a case study. Comput Biol Chem. 2014;53:242-250doi: 10.1016/j.compbiolchem.2014.09.006.
Shellman, E. R., Chen, Y., Lin, X., Burant, C. F., & Schnell, S. (2014). Metabolic network motifs can provide novel insights into evolution: The evolutionary origin of Eukaryotic organelles as a case study. Computational biology and chemistry, 53242-250. https://doi.org/10.1016/j.compbiolchem.2014.09.006
Shellman, Erin R, et al. "Metabolic network motifs can provide novel insights into evolution: The evolutionary origin of Eukaryotic organelles as a case study." Computational biology and chemistry vol. 53 (2014): 242-250. doi: https://doi.org/10.1016/j.compbiolchem.2014.09.006
Shellman ER, Chen Y, Lin X, Burant CF, Schnell S. Metabolic network motifs can provide novel insights into evolution: The evolutionary origin of Eukaryotic organelles as a case study. Comput Biol Chem. 2014 Dec;53:242-250. doi: 10.1016/j.compbiolchem.2014.09.006. Epub 2014 Sep 21. PMID: 25462333; PMCID: PMC4254655.
Copy Download .nbib Format: NLM
The Iron(III)-Phenol Complex in Aqueous Solution.

Science (New York, N.Y.)

Moeller T, Shellman RW.
PMID: 17778822
Science. 1953 Sep 18;118(3064):327-8. doi: 10.1126/science.118.3064.327.

No abstract available.

Cite
Moeller T, Shellman RW. The Iron(III)-Phenol Complex in Aqueous Solution. Science. 1953;118(3064):327-8doi: 10.1126/science.118.3064.327.
Moeller, T., & Shellman, R. W. (1953). The Iron(III)-Phenol Complex in Aqueous Solution. Science (New York, N.Y.), 118(3064), 327-8. https://doi.org/10.1126/science.118.3064.327
Moeller, T, and Shellman, R W. "The Iron(III)-Phenol Complex in Aqueous Solution." Science (New York, N.Y.) vol. 118,3064 (1953): 327-8. doi: https://doi.org/10.1126/science.118.3064.327
Moeller T, Shellman RW. The Iron(III)-Phenol Complex in Aqueous Solution. Science. 1953 Sep 18;118(3064):327-8. doi: 10.1126/science.118.3064.327. PMID: 17778822.
Copy Download .nbib Format: NLM
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy.

Cancers

Amato CM, Hintzsche JD, Wells K, Applegate A, Gorden NT, Vorwald VM, Tobin RP, Nassar K, Shellman YG, Kim J, Medina TM, Rioth M, Lewis KD, McCarter MD, Gonzalez R, Tan AC, Robinson WA.
PMID: 32708981
Cancers (Basel). 2020 Jul 17;12(7). doi: 10.3390/cancers12071943.

Immunotherapy, such as anti-PD1, has improved the survival of patients with metastatic melanoma. However, predicting which patients will respond to immunotherapy remains a significant knowledge gap. In this study we analyzed pre-immunotherapy treated tumors from 52 patients with metastatic...

Cite
Amato CM, Hintzsche JD, Wells K, et al. Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. Cancers (Basel). 2020;12(7)doi: 10.3390/cancers12071943.
Amato, C. M., Hintzsche, J. D., Wells, K., Applegate, A., Gorden, N. T., Vorwald, V. M., Tobin, R. P., Nassar, K., Shellman, Y. G., Kim, J., Medina, T. M., Rioth, M., Lewis, K. D., McCarter, M. D., Gonzalez, R., Tan, A. C., & Robinson, W. A. (2020). Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. Cancers, 12(7), . https://doi.org/10.3390/cancers12071943
Amato, Carol M, et al. "Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy." Cancers vol. 12,7 (2020). doi: https://doi.org/10.3390/cancers12071943
Amato CM, Hintzsche JD, Wells K, Applegate A, Gorden NT, Vorwald VM, Tobin RP, Nassar K, Shellman YG, Kim J, Medina TM, Rioth M, Lewis KD, McCarter MD, Gonzalez R, Tan AC, Robinson WA. Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. Cancers (Basel). 2020 Jul 17;12(7). doi: 10.3390/cancers12071943. PMID: 32708981; PMCID: PMC7409244.
Copy Download .nbib Format: NLM
Expression differences in BCL2 family members between uveal and cutaneous melanomas account for varying sensitivity to BH3 mimetics.

The Journal of investigative dermatology

Mukherjee N, Dart CR, Amato CM, Honig-Frand A, Lambert JR, Lambert KA, Robinson WA, Tobin RP, McCarter MD, Couts KL, Fujita M, Norris DA, Shellman YG.
PMID: 34942200
J Invest Dermatol. 2021 Dec 20; doi: 10.1016/j.jid.2021.11.035. Epub 2021 Dec 20.

Uveal Melanoma (UM) is a subtype of melanoma. Although they share a melanocytic origin with cutaneous melanoma (CM), patients with UM have few treatment options. BH3 mimetics are small molecule drugs that mimic pro-apoptotic BCL2 family members. We compared...

Cite
Mukherjee N, Dart CR, Amato CM, et al. Expression differences in BCL2 family members between uveal and cutaneous melanomas account for varying sensitivity to BH3 mimetics. J Invest Dermatol. 2021;doi: 10.1016/j.jid.2021.11.035.
Mukherjee, N., Dart, C. R., Amato, C. M., Honig-Frand, A., Lambert, J. R., Lambert, K. A., Robinson, W. A., Tobin, R. P., McCarter, M. D., Couts, K. L., Fujita, M., Norris, D. A., & Shellman, Y. G. (2021). Expression differences in BCL2 family members between uveal and cutaneous melanomas account for varying sensitivity to BH3 mimetics. The Journal of investigative dermatology, . https://doi.org/10.1016/j.jid.2021.11.035
Mukherjee, Nabanita, et al. "Expression differences in BCL2 family members between uveal and cutaneous melanomas account for varying sensitivity to BH3 mimetics." The Journal of investigative dermatology vol. (2021). doi: https://doi.org/10.1016/j.jid.2021.11.035
Mukherjee N, Dart CR, Amato CM, Honig-Frand A, Lambert JR, Lambert KA, Robinson WA, Tobin RP, McCarter MD, Couts KL, Fujita M, Norris DA, Shellman YG. Expression differences in BCL2 family members between uveal and cutaneous melanomas account for varying sensitivity to BH3 mimetics. J Invest Dermatol. 2021 Dec 20; doi: 10.1016/j.jid.2021.11.035. Epub 2021 Dec 20. PMID: 34942200.
Copy Download .nbib Format: NLM
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma.

Cancers

Mukherjee N, Amato CM, Skees J, Todd KJ, Lambert KA, Robinson WA, Van Gulick R, Weight RM, Dart CR, Tobin RP, McCarter MD, Fujita M, Norris DA, Shellman YG.
PMID: 32764384
Cancers (Basel). 2020 Aug 05;12(8). doi: 10.3390/cancers12082182.

There is an urgent need to develop treatments for patients with melanoma who are refractory to or ineligible for immune checkpoint blockade, including patients who lack BRAF-V600E/K mutations. This is often the case in patients diagnosed with rare melanoma...

Cite
Mukherjee N, Amato CM, Skees J, et al. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers (Basel). 2020;12(8)doi: 10.3390/cancers12082182.
Mukherjee, N., Amato, C. M., Skees, J., Todd, K. J., Lambert, K. A., Robinson, W. A., Van Gulick, R., Weight, R. M., Dart, C. R., Tobin, R. P., McCarter, M. D., Fujita, M., Norris, D. A., & Shellman, Y. G. (2020). Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers, 12(8), . https://doi.org/10.3390/cancers12082182
Mukherjee, Nabanita, et al. "Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma." Cancers vol. 12,8 (2020). doi: https://doi.org/10.3390/cancers12082182
Mukherjee N, Amato CM, Skees J, Todd KJ, Lambert KA, Robinson WA, Van Gulick R, Weight RM, Dart CR, Tobin RP, McCarter MD, Fujita M, Norris DA, Shellman YG. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers (Basel). 2020 Aug 05;12(8). doi: 10.3390/cancers12082182. PMID: 32764384; PMCID: PMC7464298.
Copy Download .nbib Format: NLM
A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension: a pilot study.

Pulmonary circulation

Brown MB, Kempf A, Collins CM, Long GM, Owens M, Gupta S, Hellman Y, Wong V, Farber M, Lahm T.
PMID: 29199900
Pulm Circ. 2018 Jan-Mar;8(1):2045893217743966. doi: 10.1177/2045893217743966.

Current evidence suggests that exercise training is beneficial in pulmonary arterial hypertension (PAH). Unfortunately, the standard supervised, hospital-based programs limit patient accessibility to this important intervention. Our proof-of-concept study aimed to provide insight into the usefulness of a prescribed...

Cite
Brown MB, Kempf A, Collins CM, et al. A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension: a pilot study. Pulm Circ. 2018;8(1):2045893217743966doi: 10.1177/2045893217743966.
Brown, M. B., Kempf, A., Collins, C. M., Long, G. M., Owens, M., Gupta, S., Hellman, Y., Wong, V., Farber, M., & Lahm, T. (2018). A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension: a pilot study. Pulmonary circulation, 8(1), 2045893217743966. https://doi.org/10.1177/2045893217743966
Brown, Mary Beth, et al. "A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension: a pilot study." Pulmonary circulation vol. 8,1 (2018): 2045893217743966. doi: https://doi.org/10.1177/2045893217743966
Brown MB, Kempf A, Collins CM, Long GM, Owens M, Gupta S, Hellman Y, Wong V, Farber M, Lahm T. A prescribed walking regimen plus arginine supplementation improves function and quality of life for patients with pulmonary arterial hypertension: a pilot study. Pulm Circ. 2018 Jan-Mar;8(1):2045893217743966. doi: 10.1177/2045893217743966. PMID: 29199900; PMCID: PMC5731727.
Copy Download .nbib Format: NLM
Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors.

Cardiac failure review

Marcusohn E, Kobo O, Postnikov M, Epstein D, Agmon Y, Gepstein L, Hellman Y, Zukermann R.
PMID: 34950506
Card Fail Rev. 2021 Nov 22;7:e16. doi: 10.15420/cfr.2021.17. eCollection 2021 Mar.

No abstract available.

Cite
Marcusohn E, Kobo O, Postnikov M, et al. Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors. Card Fail Rev. 2021;7:e16doi: 10.15420/cfr.2021.17.
Marcusohn, E., Kobo, O., Postnikov, M., Epstein, D., Agmon, Y., Gepstein, L., Hellman, Y., & Zukermann, R. (2021). Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors. Cardiac failure review, 7e16. https://doi.org/10.15420/cfr.2021.17
Marcusohn, Erez, et al. "Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors." Cardiac failure review vol. 7 (2021): e16. doi: https://doi.org/10.15420/cfr.2021.17
Marcusohn E, Kobo O, Postnikov M, Epstein D, Agmon Y, Gepstein L, Hellman Y, Zukermann R. Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors. Card Fail Rev. 2021 Nov 22;7:e16. doi: 10.15420/cfr.2021.17. eCollection 2021 Mar. PMID: 34950506; PMCID: PMC8674700.
Copy Download .nbib Format: NLM
Treatment of congestive heart failure.

The South Dakota journal of medicine and pharmacy

SPELLMAN GG.
PMID: 15395744
SD J Med Pharm. 1949 Dec;2(12):357-9.

No abstract available.

Cite
SPELLMAN GG. Treatment of congestive heart failure. SD J Med Pharm. 1949;2(12):357-9
SPELLMAN, G. G. (1949). Treatment of congestive heart failure. The South Dakota journal of medicine and pharmacy, 2(12), 357-9.
SPELLMAN, G G. "Treatment of congestive heart failure." The South Dakota journal of medicine and pharmacy vol. 2,12 (1949): 357-9.
SPELLMAN GG. Treatment of congestive heart failure. SD J Med Pharm. 1949 Dec;2(12):357-9. PMID: 15395744.
Copy Download .nbib Format: NLM
The Art and Science of Reminiscence.

Western journal of nursing research

Shellman J.
PMID: 32441216
West J Nurs Res. 2020 Oct;42(10):783. doi: 10.1177/0193945920928003. Epub 2020 May 22.

No abstract available.

Cite
Shellman J. The Art and Science of Reminiscence. West J Nurs Res. 2020;42(10):783doi: 10.1177/0193945920928003.
Shellman, J. (2020). The Art and Science of Reminiscence. Western journal of nursing research, 42(10), 783. https://doi.org/10.1177/0193945920928003
Shellman, Juliette. "The Art and Science of Reminiscence." Western journal of nursing research vol. 42,10 (2020): 783. doi: https://doi.org/10.1177/0193945920928003
Shellman J. The Art and Science of Reminiscence. West J Nurs Res. 2020 Oct;42(10):783. doi: 10.1177/0193945920928003. Epub 2020 May 22. PMID: 32441216.
Copy Download .nbib Format: NLM
Race, income and health status: implications for health education programs.

Urban health

Shellman S.
PMID: 10266028
Urban Health. 1984 Mar;13(2):42-4.

No abstract available.

Cite
Shellman S. Race, income and health status: implications for health education programs. Urban Health. 1984;13(2):42-4
Shellman, S. (1984). Race, income and health status: implications for health education programs. Urban health, 13(2), 42-4.
Shellman, S. "Race, income and health status: implications for health education programs." Urban health vol. 13,2 (1984): 42-4.
Shellman S. Race, income and health status: implications for health education programs. Urban Health. 1984 Mar;13(2):42-4. PMID: 10266028.
Copy Download .nbib Format: NLM
ABT-737 synergizes with Bortezomib to kill melanoma cells.

Biology open

Reuland SN, Goldstein NB, Partyka KA, Smith S, Luo Y, Fujita M, Gonzalez R, Lewis K, Norris DA, Shellman YG.
PMID: 23213401
Biol Open. 2012 Feb 15;1(2):92-100. doi: 10.1242/bio.2011035. Epub 2011 Nov 16.

The BH3 mimetic ABT-737 is a potent inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L), and Bcl-w. The Bcl-2 family modulates sensitivity to anticancer drugs in many cancers, including melanomas. In this study, we examined whether ABT-737 is effective in...

Cite
Reuland SN, Goldstein NB, Partyka KA, et al. ABT-737 synergizes with Bortezomib to kill melanoma cells. Biol Open. 2011;1(2):92-100doi: 10.1242/bio.2011035.
Reuland, S. N., Goldstein, N. B., Partyka, K. A., Smith, S., Luo, Y., Fujita, M., Gonzalez, R., Lewis, K., Norris, D. A., & Shellman, Y. G. (2012). ABT-737 synergizes with Bortezomib to kill melanoma cells. Biology open, 1(2), 92-100. https://doi.org/10.1242/bio.2011035
Reuland, Steven N, et al. "ABT-737 synergizes with Bortezomib to kill melanoma cells." Biology open vol. 1,2 (2012): 92-100. doi: https://doi.org/10.1242/bio.2011035
Reuland SN, Goldstein NB, Partyka KA, Smith S, Luo Y, Fujita M, Gonzalez R, Lewis K, Norris DA, Shellman YG. ABT-737 synergizes with Bortezomib to kill melanoma cells. Biol Open. 2012 Feb 15;1(2):92-100. doi: 10.1242/bio.2011035. Epub 2011 Nov 16. PMID: 23213401; PMCID: PMC3507205.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries